Chris JacobsBuy
Amylyx Pharmaceuticals, Inc. · Transaction Oct 12, 2022 · Filed Nov 16, 2022 · $1,001 to $15,000
XNAS · AMLX
-1.03% · -$0.2900 · Vol 912.4K
After hours · updated 16:01:09 ET
Amylyx Pharmaceuticals, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
$27.79
Follow $AMLX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $AMLX by emailVeridion Score
BETALOW CONF · 6 of 6 factors measuredFri Oct 2 · session closed · Markets closed · resumes Mon 9:30 ET · AMLX
MethodologyAMLX
Amylyx Pharmaceuticals, Inc. Common Stock
Fri Oct 2 · session closed · Markets closed · resumes Mon 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
59/ 100
Veridion Score
Middle range · LOW confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6 of 6 factors measured · Fri Oct 2 · session closed · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is AMLX moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Amylyx Pharmaceuticals, Inc. Common Stock
PHARMACEUTICAL PREPARATIONSListed since
2022
Employees
136
Country
US
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$28.50
Day high
$28.81
Day low
$27.64
Previous close
$28.08
52W high
$39.66
-29.93% from high
52W low
$11.38
58% of range
Market cap
$3.6B
Beta
0.51
Shares out
127.6M
Volume
912.4K
0.52× rel vol
Avg volume
1.8M
VWAP
$28.01
Price history computed in-house
1W
-5.76%
1M
-19.43%
3M
+52.11%
1Y
+109.10%
YTD
+130.05%
SMA 50 $29.33 · below
SMA 200 $18.52 · above
52W position 58%
AMLX overview
Related filings and maps
Public disclosures
Congress activity in AMLX
Official filing ↗
Federal contracts
AMLX contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AMLX in this window.
Lobbying spend
AMLX lobbying filings, year to date.
Registered lobbying filings matched to Amylyx Pharmaceuticals, Inc. Common Stock.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AMLX in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for AMLX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.